Do analysts recommend GCTK or ICU?

SeaStar Medical has a consensus target price of $8.00, suggesting a potential upside of 143.90%. Given SeaStar Medical's stronger consensus rating and higher possible upside, analysts plainly believe SeaStar Medical is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SeaStar Medical 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend SURG or GCTK?

SurgePays currently has a consensus price target of $5.00, indicating a potential upside of 851.29%. Given SurgePays' stronger consensus rating and higher probable upside, research analysts plainly believe SurgePays is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SurgePays 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SURG or GCTK more profitable?

GlucoTrack has a net margin of 0.00% compared to SurgePays' net margin of -64.91%. GlucoTrack's return on equity of -581.98% beat SurgePays' return on equity. Company Net Margins Return on Equity Return on Assets SurgePays -64.91% -967.32% -310.16% GlucoTrack N/A -581.98% -220.10%

Does the media favor SURG or GCTK?

In the previous week, SurgePays and SurgePays both had 2 articles in the media. GlucoTrack's average media sentiment score of 0.96 beat SurgePays' score of 0.77 indicating that GlucoTrack is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SurgePays 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive GlucoTrack 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MBAI or GCTK?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, MBAI or GCTK?

Check-Cap is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Check-Cap N/A N/A $4.14M -$2.77 N/A GlucoTrack N/A N/A -$19.39M -$18.04 N/A

Is MBAI or GCTK more profitable?

Check-Cap's return on equity of 0.00% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets Check-Cap N/A N/A N/A GlucoTrack N/A -581.98% -220.10%

Does the media favor MBAI or GCTK?

In the previous week, Check-Cap and Check-Cap both had 2 articles in the media. GlucoTrack's average media sentiment score of 0.96 beat Check-Cap's score of 0.94 indicating that GlucoTrack is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Check-Cap 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GlucoTrack 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ALUR or GCTK?

Allurion Technologies currently has a consensus target price of $3.00, suggesting a potential upside of 250.88%. Given Allurion Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Allurion Technologies is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allurion Technologies 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to ALUR or GCTK?

In the previous week, GlucoTrack had 1 more articles in the media than Allurion Technologies. MarketBeat recorded 2 mentions for GlucoTrack and 1 mentions for Allurion Technologies. Allurion Technologies' average media sentiment score of 1.42 beat GlucoTrack's score of 0.96 indicating that Allurion Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allurion Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GlucoTrack 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer GCTK or LFWD?

Lifeward has a consensus price target of $10.00, indicating a potential upside of 37.36%. Given Lifeward's stronger consensus rating and higher possible upside, analysts plainly believe Lifeward is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lifeward 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is GCTK or LFWD more profitable?

GlucoTrack has a net margin of 0.00% compared to Lifeward's net margin of -123.66%. Lifeward's return on equity of -243.14% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets GlucoTrack N/A -581.98% -220.10% Lifeward -123.66% -243.14% -97.39%

GlucoTrack (GCTK) Competitors

$0.67 +0.00 (+0.67%)

Closing price 04:00 PM Eastern

Extended Trading

$0.67 +0.00 (+0.54%)

As of 07:45 PM Eastern

Compare

GCTK vs. ICU, SURG, MBAI, ALUR, and LFWD

Should you buy GlucoTrack stock or one of its competitors? MarketBeat compares GlucoTrack with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GlucoTrack include SeaStar Medical (ICU), SurgePays (SURG), Check-Cap (MBAI), Allurion Technologies (ALUR), and Lifeward (LFWD). These companies are all part of the "medical equipment" industry.

How does GlucoTrack compare to SeaStar Medical?

GlucoTrack (NASDAQ:GCTK) and SeaStar Medical (NASDAQ:ICU) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

SeaStar Medical has higher revenue and earnings than GlucoTrack. SeaStar Medical is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A
SeaStar Medical	$1.23M	10.67	-$12.15M	-$4.80	N/A

SeaStar Medical has a consensus target price of $8.00, suggesting a potential upside of 143.90%. Given SeaStar Medical's stronger consensus rating and higher possible upside, analysts plainly believe SeaStar Medical is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SeaStar Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, GlucoTrack had 1 more articles in the media than SeaStar Medical. MarketBeat recorded 2 mentions for GlucoTrack and 1 mentions for SeaStar Medical. SeaStar Medical's average media sentiment score of 1.89 beat GlucoTrack's score of 0.96 indicating that SeaStar Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
GlucoTrack	Positive
SeaStar Medical	Very Positive

GlucoTrack has a net margin of 0.00% compared to SeaStar Medical's net margin of -828.62%. SeaStar Medical's return on equity of -146.29% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-581.98%	-220.10%
SeaStar Medical	-828.62%	-146.29%	-96.48%

10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 1.7% of SeaStar Medical shares are owned by institutional investors. 2.2% of GlucoTrack shares are owned by company insiders. Comparatively, 0.7% of SeaStar Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

GlucoTrack has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, SeaStar Medical has a beta of -1.05, indicating that its share price is 205% less volatile than the broader market.

Summary

SeaStar Medical beats GlucoTrack on 9 of the 15 factors compared between the two stocks.

How does GlucoTrack compare to SurgePays?

SurgePays (NASDAQ:SURG) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

6.9% of SurgePays shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 29.1% of SurgePays shares are held by company insiders. Comparatively, 2.2% of GlucoTrack shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

SurgePays currently has a consensus price target of $5.00, indicating a potential upside of 851.29%. Given SurgePays' stronger consensus rating and higher probable upside, research analysts plainly believe SurgePays is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SurgePays	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, SurgePays and SurgePays both had 2 articles in the media. GlucoTrack's average media sentiment score of 0.96 beat SurgePays' score of 0.77 indicating that GlucoTrack is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SurgePays	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
GlucoTrack	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GlucoTrack has lower revenue, but higher earnings than SurgePays. SurgePays is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SurgePays	$56.96M	0.23	-$36.07M	-$1.94	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A

SurgePays has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

GlucoTrack has a net margin of 0.00% compared to SurgePays' net margin of -64.91%. GlucoTrack's return on equity of -581.98% beat SurgePays' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SurgePays	-64.91%	-967.32%	-310.16%
GlucoTrack	N/A	-581.98%	-220.10%

Summary

GlucoTrack beats SurgePays on 8 of the 14 factors compared between the two stocks.

How does GlucoTrack compare to Check-Cap?

Check-Cap (NASDAQ:MBAI) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Check-Cap and Check-Cap both had 2 articles in the media. GlucoTrack's average media sentiment score of 0.96 beat Check-Cap's score of 0.94 indicating that GlucoTrack is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Check-Cap	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GlucoTrack	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Check-Cap's return on equity of 0.00% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
GlucoTrack	N/A	-581.98%	-220.10%

Check-Cap is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A

Check-Cap has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 0.5% of Check-Cap shares are held by company insiders. Comparatively, 2.2% of GlucoTrack shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

GlucoTrack beats Check-Cap on 5 of the 9 factors compared between the two stocks.

How does GlucoTrack compare to Allurion Technologies?

Allurion Technologies (NYSE:ALUR) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

In the previous week, GlucoTrack had 1 more articles in the media than Allurion Technologies. MarketBeat recorded 2 mentions for GlucoTrack and 1 mentions for Allurion Technologies. Allurion Technologies' average media sentiment score of 1.42 beat GlucoTrack's score of 0.96 indicating that Allurion Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allurion Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GlucoTrack	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

21.4% of Allurion Technologies shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 8.1% of Allurion Technologies shares are held by insiders. Comparatively, 2.2% of GlucoTrack shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Allurion Technologies currently has a consensus target price of $3.00, suggesting a potential upside of 250.88%. Given Allurion Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Allurion Technologies is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

GlucoTrack has a net margin of 0.00% compared to Allurion Technologies' net margin of -199.96%. Allurion Technologies' return on equity of 0.00% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-199.96%	N/A	-77.13%
GlucoTrack	N/A	-581.98%	-220.10%

Allurion Technologies has higher revenue and earnings than GlucoTrack. Allurion Technologies is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$17.21M	0.74	-$7.20M	-$1.75	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A

Allurion Technologies has a beta of -0.18, meaning that its stock price is 118% less volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

Summary

Allurion Technologies beats GlucoTrack on 11 of the 15 factors compared between the two stocks.

How does GlucoTrack compare to Lifeward?

GlucoTrack (NASDAQ:GCTK) and Lifeward (NASDAQ:LFWD) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Lifeward has a consensus price target of $10.00, indicating a potential upside of 37.36%. Given Lifeward's stronger consensus rating and higher possible upside, analysts plainly believe Lifeward is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lifeward	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Lifeward had 4 more articles in the media than GlucoTrack. MarketBeat recorded 6 mentions for Lifeward and 2 mentions for GlucoTrack. Lifeward's average media sentiment score of 1.47 beat GlucoTrack's score of 0.96 indicating that Lifeward is being referred to more favorably in the news media.

Company	Overall Sentiment
GlucoTrack	Positive
Lifeward	Positive

GlucoTrack has higher earnings, but lower revenue than Lifeward. Lifeward is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$18.04	N/A
Lifeward	$22.03M	0.93	-$19.91M	-$19.66	N/A

GlucoTrack has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Lifeward has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

GlucoTrack has a net margin of 0.00% compared to Lifeward's net margin of -123.66%. Lifeward's return on equity of -243.14% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-581.98%	-220.10%
Lifeward	-123.66%	-243.14%	-97.39%

10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 26.8% of Lifeward shares are held by institutional investors. 2.2% of GlucoTrack shares are held by insiders. Comparatively, 1.5% of Lifeward shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Lifeward beats GlucoTrack on 9 of the 15 factors compared between the two stocks.

Get GlucoTrack News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GCTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GCTK vs. The Competition

Export

Metric	GlucoTrack	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.14M	$8.16B	$6.47B	$12.54B
Dividend Yield	N/A	2.61%	2.69%	5.22%
P/E Ratio	-0.04	12.43	18.89	22.53
Price / Sales	N/A	7.06	520.79	112.26
Price / Cash	N/A	17.10	41.34	57.13
Price / Book	0.24	3.53	9.84	6.72
Net Income	-$19.39M	$224.05M	$3.57B	$337.19M
7 Day Performance	4.46%	-1.09%	-1.16%	0.48%
1 Month Performance	-16.83%	0.34%	3.85%	5.07%
1 Year Performance	-92.24%	-0.29%	27.40%	34.25%

GlucoTrack Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GCTK GlucoTrack	1.0728 of 5 stars	$0.67 +0.7%	N/A	-91.3%	$4.14M	N/A	N/A	5
ICU SeaStar Medical	3.0199 of 5 stars	$3.59 +0.3%	$8.00 +122.8%	-70.1%	$14.31M	$1.23M	N/A	2	Positive News
SURG SurgePays	3.0757 of 5 stars	$0.55 +9.0%	$5.00 +807.4%	-81.3%	$12.70M	$56.96M	N/A	40	Short Interest Decrease
MBAI Check-Cap	0.2751 of 5 stars	$1.70 -1.2%	N/A	N/A	$12.54M	N/A	N/A	80	Gap Down
ALUR Allurion Technologies	1.9539 of 5 stars	$0.80 flat	$3.00 +275.0%	-73.5%	$12.00M	$17.21M	N/A	501	News Coverage Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GCTK) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GlucoTrack (GCTK) Competitors

GCTK vs. ICU, SURG, MBAI, ALUR, and LFWD

How does GlucoTrack compare to SeaStar Medical?

Summary

How does GlucoTrack compare to SurgePays?

Summary

How does GlucoTrack compare to Check-Cap?

Summary

How does GlucoTrack compare to Allurion Technologies?

Summary

How does GlucoTrack compare to Lifeward?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GCTK vs. The Competition

GlucoTrack Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GlucoTrack (GCTK) Competitors

GCTK vs. ICU, SURG, MBAI, ALUR, and LFWD

How does GlucoTrack compare to SeaStar Medical?

Which has better earnings and valuation, GCTK or ICU?

Do analysts recommend GCTK or ICU?

Does the media refer more to GCTK or ICU?

Is GCTK or ICU more profitable?

Do institutionals & insiders hold more shares of GCTK or ICU?

Which has more risk and volatility, GCTK or ICU?

Summary

How does GlucoTrack compare to SurgePays?

Do insiders & institutionals believe in SURG or GCTK?

Do analysts recommend SURG or GCTK?

Does the media favor SURG or GCTK?

Which has stronger valuation and earnings, SURG or GCTK?

Which has more volatility and risk, SURG or GCTK?

Is SURG or GCTK more profitable?

Summary

How does GlucoTrack compare to Check-Cap?

Do analysts recommend MBAI or GCTK?

Does the media favor MBAI or GCTK?

Is MBAI or GCTK more profitable?

Which has stronger valuation and earnings, MBAI or GCTK?

Which has more volatility and risk, MBAI or GCTK?

Do insiders & institutionals believe in MBAI or GCTK?

Summary

How does GlucoTrack compare to Allurion Technologies?

Does the media refer more to ALUR or GCTK?

Do insiders & institutionals have more ownership in ALUR or GCTK?

Do analysts prefer ALUR or GCTK?

Is ALUR or GCTK more profitable?

Which has preferable earnings & valuation, ALUR or GCTK?

Which has more risk and volatility, ALUR or GCTK?

Summary

How does GlucoTrack compare to Lifeward?

Do analysts prefer GCTK or LFWD?

Does the media prefer GCTK or LFWD?

Which has higher valuation & earnings, GCTK or LFWD?

Which has more risk & volatility, GCTK or LFWD?

Is GCTK or LFWD more profitable?

Do insiders and institutionals believe in GCTK or LFWD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GCTK vs. The Competition

GlucoTrack Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools